

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT  
APPLICATION

In re: PATENT APPLICATION of:

Inventor(s): ZEICHER

Appln. No.: 08 807,500

Series Code ↑ Serial No. ↑

Filed: February 27, 1997

Title: NUCLEOTIDE SEQUENCE FOR TREATING  
CANCER ETC.

Group Art Unit 1635

Examiner: S. McGarry

Atty. Dkt. PM 236007

PZCOM01/USC

M#

Client Ref

**DO NOT USE FOR PROVISIONAL,  
DIVISIONAL, CIP OR DESIGN  
APPLICATIONS, OR REEXAMINATION OF  
PATENTS**Hon. Commissioner of Patents  
Washington, D.C. 20231

Date: February 5, 2001

Sir:

**REQUEST FOR CONTINUED EXAMINATION (RCE) UNDER RULE 114**

Please continue the examination of this application.

**PREREQUISITES**This application was filed on/after June 8, 1995, is not abandoned, and no court action has been filed, or if filed, it has been terminated.An issue fee **has not been** paid (unless a petition under Rule 313(c)(2) is also being filed -- see item 4 below).**Prosecution has been closed as defined in Rule 114(b).****Reply to any outstanding action and Rule 17(e) fee must be enclosed**

This application is entitled under Rule to withdrawal of any outstanding finality or of any allowance plus a new action by the Examiner. Consideration on the merits of each submission (e.g., IDS, Amendment, new arguments, new evidence, but not appeal/reply briefs themselves) filed herewith or before the new action is respectfully requested.

Please consider the following in before the next Official Action:

1. Please ☐ enter ☐ do not enter the Amendment filed \_\_\_\_\_
2. ☐ The enclosed new Amendment
3. ☐ Consider the arguments in the appeal brief filed \_\_\_\_\_ and reply brief filed \_\_\_\_\_
4. ☐ The issue fee has been paid, but this RCE is based on Rule 313(c)(2). See enclosed petition.
5. ☐ The enclosed Information Disclosure Statement  
☐ IDS Letter ☐ Cited Appln ☐ Foreign Search Report/OA  
☐ PTO-1449 ☐ Cited Documents
6. ☒ Please suspend action under Rule 103(c) for a period of three months (3 mos. Max) for which the required \$130 fee is enclosed

(Our Deposit Account No. 03-3975)

(Our Order No. 70401 / 236007 )

C#

M#

**NOTE: Enter Rule 17(e) filing fee on PAT-120 for it  
Cannot be deferred!****NO CLAIMS FEE REQUIRED****CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee, specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.**This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.**Pillsbury Winthrop LLP  
Intellectual Property Group1100 New York Avenue, NW  
Ninth Floor  
Washington, DC 20005-3918  
(202) 861-3000  
Atty/Sec: ASH/LMR

By Atty: Ann S. Hobbs

Sig: C. S. Hobbs

Reg. No. 36830

Fax: (202) 822-0944

Tel: (202) 861-3063

**NOTE: File this Request (plus enclosures, if any) with cover sheet (PAT-120) in duplicate and with PTO receipt (PAT-103A)**

02/06/2001 HVUONG1 00000075 08807500

01 FC-20743315\_1.DOC

355.00 0P

PAT-252 12/00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): ZEICHER

Appln. No.: 08

807,500

Series Code ↑

Serial No. ↑

Filed: February 27, 1997

Hon. Commissioner of Patents

Washington, D.C. 20231

Group Art Unit 1635

Examiner: S. McGarry

Atty. Dkt. PM 236007

PZCOM01/USC

Appln. Title: NUCLEOTIDE SEQUENCE  
TREATING CANCER ETC.

TECH CENTER 1600/2300

Date: February 5, 2001

## REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

## FEE REQUIREMENTS FOR CLAIMS AS AMENDED

## 1. Small Entity claim

A. ☐ NOT madeB. ☐ WithdrawnC. ☐ made herewithD. ☒ made previously

For B &amp; C

See **Required****Separate Paper**

(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus 20	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus 3	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) ..... add			+ \$270/\$135 =	+ \$0	104/204
5. Original due Date: September 3, 2000 <input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached (1 mo) \$110/\$55 = (2 mos) \$390/\$195 = (3 mos) \$890/\$445 = (Usable only for ≤ 2mo.OA --- 4 mos) \$1390/\$695= (Usable only for 30 day/1mo.OA --- 5 mos) \$1890/\$945=			+ \$945		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8. Extension Fee Attached			+ \$945		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee .....			+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c), ..... add			+ \$180	+ \$0	126
or if Rule 97(d) Request ..... add			+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r) .....			+ \$710/355	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b).....			x \$710/355 ea	+ \$0	149/249
13. Request for Continued Examination (RCE) .....			+ \$710/355	+ \$355	1179/1279
14. Petition fee for Suspension of Action Under Rule 103(c) .....			+ \$130		
15. TOTAL FEE ENCLOSED =				\$1430	

16. \*If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

02/06/2001 HUUONG1 00000075 08807500

Our Deposit Account No. 03-3975)

02 FC:228

945.00 0P

(Our Order No. 70401

236007

C#

M#

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT **does not authorize** charge of the **issue fee** until/unless an Issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

02/06/2001 HUUONG1 00000075 08807500

03 FC:120 New York Avenue, NW 130.00 0P

Ninth Floor

Washington, DC 20005-3918

Tel: (202) 861-3000

Atty/Sec: ASH/LMR

Pillsbury Winthrop LLP

Intellectual Property Group

By Atty: Ann S. Hobbs

Sig:

Reg. No. 36830

Fax: (202) 822-0944

Tel: (202) 861-3063

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments